

Please amend claim 33 as follows:

33 (Once amended). A method for directly identifying a candidate compound as a compound having activity selected from the group consisting of [an] inverse agonist activity, [a] partial agonist activity and [an] agonist activity, to a non-endogenous constitutively activated G protein coupled cell surface orphan receptor, comprising the steps of:

- B2 Sub C2
- (a) contacting a candidate compound with a non-endogenous constitutively activated G protein coupled cell surface orphan receptor; and
 - (b) determining, by measurement of the compound efficacy at said contacted receptor, whether said compound [is an] has inverse agonist activity, [a] partial agonist activity, or [an] agonist activity [of] to said receptor.

Please amend claim 34 as follows:

34 (Once amended). The method of claim 33 wherein the candidate compound is [determined to be an] directly identified as having inverse agonist activity at [of] said receptor.

Please amend claim 39 as follows:

Sub E2 39 (Once amended). A method for directly identifying a candidate compound as a compound having activity selected from the group consisting of [an] inverse agonist activity, [a] partial agonist activity and [an] agonist activity, to an endogenous constitutively activated G protein coupled cell surface orphan receptor, comprising the steps of:

- B3 Sub Cn
- (a) contacting a candidate compound with an endogenous constitutively activated G protein coupled cell surface orphan receptor; and
 - (b) determining, by measurement of the compound efficacy at said contacted receptor, whether said compound [is an] has inverse agonist activity, [a] partial agonist activity, or [an] agonist activity [of] to said receptor.

Please amend claim 40 as follows:

40 (Once amended). The method of claim 39 wherein the candidate compound is [determined to be an] directly identified as having inverse agonist activity at [of] said receptor.

Support for these changes may be found throughout the Specification; for example, please see page 64, lines 13-18 and Example 4.

Respectfully submitted,

Dated: 10.14.99

By: 

Richard P. Burgeon, Jr.
Reg. No. 34,787

ARENA PHARMACEUTICALS, INC.
6166 Nancy Ridge Drive
San Diego, CA 92121